Alzheimer's disease genetics: From the bench to the clinic

Neuron

Volumn 83, Issue 1, 2014, Pages 11-26

  Karch, Celeste M ^a   Cruchaga, Carlos ^a   Goate, Alison M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE 1; BIOLOGICAL MARKER; CD2 ASSOCIATED PROTEIN; CD33 ANTIGEN; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; EPHRIN RECEPTOR A1; PRESENILIN 1; PRESENILIN 2; PROGRANULIN; TAU PROTEIN;

ABCA7 GENE; ADAM10 GENE; ALZHEIMER DISEASE; APP GENE; BACE1 GENE; BIN1 GENE; C9ORF72 GENE; CASE CONTROL STUDY; CD2AP GENE; CD33 GENE; CLU GENE; DEMENTIA; ENDOCYTOSIS; EPHA1 GENE; GENE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GRN GENE; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; MAPT GENE; MOLECULAR GENETICS; NEUROIMAGING; NONHUMAN; PICALM GENE; PLD3 GENE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PSEN1 GENE; PSEN2 GENE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SORL1 GENE; TREM2 GENE;

ALZHEIMER DISEASE; ANIMALS; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; PHARMACOGENETICS;

EID: 84903627137     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.05.041     Document Type: Review

References (174)

1. Alexopoulos P., Guo L.H., Kratzer M., Westerteicher C., Kurz A., Perneczky R. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers. Dement. Geriatr. Cogn. Disord. 2011, 32:164-170.
2. Arango D., Cruts M., Torres O., Backhovens H., Serrano M.L., Villareal E., Montañes P., Matallana D., Cano C., Van Broeckhoven C., Jacquier M. Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. Am. J. Med. Genet. 2001, 103:138-143.
3. Ball R.D. Designing a GWAS: power, sample size, and data structure. Methods Mol. Biol. 2013, 1019:37-98.
4. Bateman R.J., Aisen P.S., De Strooper B., Fox N.C., Lemere C.A., Ringman J.M., Salloway S., Sperling R.A., Windisch M., Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011, 3:1.
5. Benitez B.A., Karch C.M., Cai Y., Jin S.C., Cooper B., Carrell D., Bertelsen S., Chibnik L., Schneider J.A., Bennett D.A., et al. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers. PLoS Genet. 2013, 9:e1003685. Alzheimer's Disease Neuroimaging Initiative, Genetic and Environmental Risk for Alzheimer's Disease Consortium GERADGenetic and Environmental Risk for Alzheimer's Disease Consortium GERAD.
6. Benitez B.A., Jin S.C., Guerreiro R., Graham R., Lord J., Harold D., Sims R., Lambert J.C., Gibbs J.R., Bras J., et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol. Aging 2014, 35:e19-e26. 3C Study Group, EADI consortiumEADI consortium, Alzheimer's Disease Genetic Consortium (ADGC)Alzheimer's Disease Genetic Consortium (ADGC), Alzheimer's Disease Neuroimaging Initiative (ADNI)Alzheimer's Disease Neuroimaging Initiative (ADNI), GERAD ConsortiumGERAD Consortium.
7. Bergmans B.A., De Strooper B. gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010, 9:215-226.
8. Bertram L., Lange C., Mullin K., Parkinson M., Hsiao M., Hogan M.F., Schjeide B.M., Hooli B., Divito J., Ionita I., et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 2008, 83:623-632.
9. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 2010, 68:270-281.
10. Biffi A., Anderson C.D., Desikan R.S., Sabuncu M., Cortellini L., Schmansky N., Salat D., Rosand J. Genetic variation and neuroimaging measures in Alzheimer disease. Arch. Neurol. 2010, 67:677-685. Alzheimer's Disease Neuroimaging Initiative (ADNI).
11. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
12. Bralten J., Arias-Vásquez A., Makkinje R., Veltman J.A., Brunner H.G., Fernández G., Rijpkema M., Franke B. Association of the Alzheimer's gene SORL1 with hippocampal volume in young, healthy adults. Am. J. Psychiatry 2011, 168:1083-1089.
13. Braskie M.N., Jahanshad N., Stein J.L., Barysheva M., McMahon K.L., de Zubicaray G.I., Martin N.G., Wright M.J., Ringman J.M., Toga A.W., Thompson P.M. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J.Neurosci. 2011, 31:6764-6770.
14. Brouwers N., Nuytemans K., van der Zee J., Gijselinck I., Engelborghs S., Theuns J., Kumar-Singh S., Pickut B.A., Pals P., Dermaut B., et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch. Neurol. 2007, 64:1436-1446.
15. Brouwers N., Sleegers K., Engelborghs S., Maurer-Stroh S., Gijselinck I., van der Zee J., Pickut B.A., Van den Broeck M., Mattheijssens M., Peeters K., et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 2008, 71:656-664.
16. Cai D., Netzer W.J., Zhong M., Lin Y., Du G., Frohman M., Foster D.A., Sisodia S.S., Xu H., Gorelick F.S., Greengard P. Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc. Natl. Acad. Sci. USA 2006, 103:1941-1946.
17. Cai D., Zhong M., Wang R., Netzer W.J., Shields D., Zheng H., Sisodia S.S., Foster D.A., Gorelick F.S., Xu H., Greengard P. Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc. Natl. Acad. Sci. USA 2006, 103:1936-1940.
18. Carecchio M., Fenoglio C., De Riz M., Guidi I., Comi C., Cortini F., Venturelli E., Restelli I., Cantoni C., Bresolin N., et al. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. J.Neurol. Sci. 2009, 287:291-293.
19. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
20. Chan S.L., Kim W.S., Kwok J.B., Hill A.F., Cappai R., Rye K.A., Garner B. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein invitro. J.Neurochem. 2008, 106:793-804.
21. Chapuis J., Hansmannel F., Gistelinck M., Mounier A., Van Cauwenberghe C., Kolen K.V., Geller F., Sottejeau Y., Harold D., Dourlen P., et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol. Psychiatry 2013, 18:1225-1234. GERAD consortium.
22. Chávez-Gutiérrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., Lismont S., Zhou L., Van Cleynenbreugel S., Esselmann H., et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012, 31:2261-2274.
23. Chen K., Langbaum J.B., Fleisher A.S., Ayutyanont N., Reschke C., Lee W., Liu X., Bandy D., Alexander G.E., Thompson P.M., et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage 2010, 51:654-664. Alzheimer's Disease Neuroimaging Initiative.
24. Chouraki V., De Bruijn R.F., Chapuis J., Bis J.C., Reitz C., Schraen S., Ibrahim-Verbaas C.A., Grenier-Boley B., Delay C., Rogers R., et al. A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly. Mol. Psychiatry 2014, The Alzheimer's Disease Neuroimaging Initiative, Published online February 18, 2014. 10.1038/mp.2013.185.
25. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels invivo. Neuron 2005, 48:913-922.
26. Cirrito J.R., Kang J.-E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta invivo. Neuron 2008, 58:42-51.
27. Colonna M. TREMs in the immune system and beyond. Nat. Rev. Immunol. 2003, 3:445-453.
28. Cortini F., Fenoglio C., Guidi I., Venturelli E., Pomati S., Marcone A., Scalabrini D., Villa C., Clerici F., Dalla Valle E., et al. Novel exon 1 progranulin gene variant in Alzheimer's disease. Eur. J. Neurol. 2008, 15:1111-1117.
29. Craig-Schapiro R., Fagan A.M., Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol. Dis. 2009, 35:128-140.
30. Cruchaga C., Kauwe J.S.K., Mayo K., Spiegel N., Bertelsen S., Nowotny P., Shah A.R., Abraham R., Hollingworth P., Harold D., et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet. 2010, 6:e1001101. Alzheimer's Disease Neuroimaging Initiative.
31. Cruchaga C., Haller G., Chakraverty S., Mayo K., Vallania F.L., Mitra R.D., Faber K., Williamson J., Bird T., Diaz-Arrastia R., et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS ONE 2012, 7:e31039. NIA-LOAD/NCRAD Family Study Consortium.
32. Cruchaga C., Kauwe J.S., Nowotny P., Bales K., Pickering E.H., Mayo K., Bertelsen S., Hinrichs A., Fagan A.M., Holtzman D.M., et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 2012, 21:4558-4571. Alzheimer's Disease Neuroimaging Initiative.
33. Cruchaga C., Kauwe J.S., Harari O., Jin S.C., Cai Y., Karch C.M., Benitez B.A., Jeng A.T., Skorupa T., Carrell D., et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 2013, 78:256-268. GERAD Consortium, Alzheimer's Disease Neuroimaging Initiative (ADNI)Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimer Disease Genetic Consortium (ADGC)Alzheimer Disease Genetic Consortium (ADGC).
34. Cruchaga C., Karch C.M., Jin S.C., Benitez B.A., Cai Y., Guerreiro R., Harari O., Norton J., Budde J., Bertelsen S., et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 2014, 505:550-554. UK Brain Expression Consortium, Alzheimer's Research UK ConsortiumAlzheimer's Research UK Consortium.
35. Cuyvers E., Bettens K., Philtjens S., Van Langenhove T., Gijselinck I., van der Zee J., Engelborghs S., Vandenbulcke M., Van Dongen J., Geerts N., et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol. Aging 2014, 35:e11-e19. BELNEU consortium.
36. Damoiseaux J.S., Seeley W.W., Zhou J., Shirer W.R., Coppola G., Karydas A., Rosen H.J., Miller B.L., Kramer J.H., Greicius M.D. Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J.Neurosci. 2012, 32:8254-8262. Alzheimer's Disease Neuroimaging Initiative.
37. de Silva R., Weiler M., Morris H.R., Martin E.R., Wood N.W., Lees A.J. Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. Neurosci. Lett. 2001, 311:145-148.
38. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003, 38:9-12.
39. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
40. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism invivo. Neuron 2004, 41:193-202.
41. Devi G., Fotiou A., Jyrinji D., Tycko B., DeArmand S., Rogaeva E., Song Y.Q., Medieros H., Liang Y., Orlacchio A., et al. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch. Neurol. 2000, 57:1454-1457.
42. Di Fede G., Catania M., Morbin M., Rossi G., Suardi S., Mazzoleni G., Merlin M., Giovagnoli A.R., Prioni S., Erbetta A., et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
43. Dustin M.L., Olszowy M.W., Holdorf A.D., Li J., Bromley S., Desai N., Widder P., Rosenberger F., van der Merwe P.A., Allen P.M., Shaw A.S. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 1998, 94:667-677.
44. Elias-Sonnenschein L.S., Helisalmi S., Natunen T., Hall A., Paajanen T., Herukka S.K., Laitinen M., Remes A.M., Koivisto A.M., Mattila K.M., et al. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort. PLoS ONE 2013, 8:e59676.
45. Erk S., Meyer-Lindenberg A., Opitz von Boberfeld C., Esslinger C., Schnell K., Kirsch P., Mattheisen M., Mühleisen T.W., Cichon S., Witt S.H., et al. Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. J.Neurosci. 2011, 31:18180-18184.
46. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., Holtzman D.M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2002, 9:305-318.
47. Fagan A.M., Xiong C., Jasielec M.S., Bateman R.J., Goate A.M., Benzinger T.L., Ghetti B., Martins R.N., Masters C.L., Mayeux R., et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci. Transl. Med. 2014, 6:26ra30. Dominantly Inherited Alzheimer Network.
48. Forabosco P., Ramasamy A., Trabzuni D., Walker R., Smith C., Bras J., Levine A.P., Hardy J., Pocock J.M., Guerreiro R., et al. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol. Aging 2013, 34:2699-2714.
49. Furney S.J., Simmons A., Breen G., Pedroso I., Lunnon K., Proitsi P., Hodges A., Powell J., Wahlund L.O., Kloszewska I., et al. Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol. Psychiatry 2011, 16:1130-1138. Alzheimer's Disease Neuroimaging Initiative, AddNeuroMed ConsortiumAddNeuroMed Consortium.
50. Griciuc A., Serrano-Pozo A., Parrado A.R., Lesinski A.N., Asselin C.N., Mullin K., Hooli B., Choi S.H., Hyman B.T., Tanzi R.E. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
51. Guerreiro R., Hardy J. TREM2 and neurodegenerative disease. N.Engl. J. Med. 2013, 369:1569-1570.
52. Guerreiro R.J., Baquero M., Blesa R., Boada M., Brás J.M., Bullido M.J., Calado A., Crook R., Ferreira C., Frank A., et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol. Aging 2010, 31:725-731.
53. Guerreiro R.J., Gustafson D.R., Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol. Aging 2012, 33:437-456.
54. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 variants in Alzheimer's disease. N.Engl. J. Med. 2013, 368:117-127. Alzheimer Genetic Analysis Group.
55. Guerreiro R.J., Lohmann E., Brás J.M., Gibbs J.R., Rohrer J.D., Gurunlian N., Dursun B., Bilgic B., Hanagasi H., Gurvit H., et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013, 70:78-84.
56. Han M.R., Schellenberg G.D., Wang L.S. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol. 2010, 10:90. Alzheimer's Disease Neuroimaging Initiative.
57. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
58. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
59. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J.-C., Carrasquillo M.M., Abraham R., Hamshere M.L., Pahwa J.S., Moskvina V., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43:429-435. Alzheimer's Disease Neuroimaging Initiative, CHARGE consortiumCHARGE consortium, EADI1 consortiumEADI1 consortium.
60. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000, 97:2892-2897.
61. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 2011, 3:sr1.
62. Holtzman D.M., Herz J., Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006312.
63. Hong M.G., Reynolds C.A., Feldman A.L., Kallin M., Lambert J.C., Amouyel P., Ingelsson E., Pedersen N.L., Prince J.A. Genome-wide and gene-based association implicates FRMD6 in Alzheimer disease. Hum. Mutat. 2012, 33:521-529.
64. Hruska K.S., LaMarca M.E., Scott C.R., Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 2008, 29:567-583.
65. Huey E.D., Grafman J., Wassermann E.M., Pietrini P., Tierney M.C., Ghetti B., Spina S., Baker M., Hutton M., Elder J.W., et al. Characteristics of frontotemporal dementia patients with a Progranulin mutation. Ann. Neurol. 2006, 60:374-380.
66. Jagust W.J., Landau S.M. Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J.Neurosci. 2012, 32:18227-18233. Alzheimer's Disease Neuroimaging Initiative.
67. Jayadev S., Leverenz J.B., Steinbart E., Stahl J., Klunk W., Yu C.E., Bird T.D. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 2010, 133:1143-1154.
68. Jin S.C., Pastor P., Cooper B., Cervantes S., Benitez B.A., Razquin C., Goate A., Cruchaga C. Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. Alzheimers Res Ther 2012, 4:34. Ibero-American Alzheimer Disease Genetics Group Researchers.
69. Jones L., Holmans P.A., Hamshere M.L., Harold D., Moskvina V., Ivanov D., Pocklington A., Abraham R., Hollingworth P., Sims R., et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 2010, 5:e13950.
70. Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
71. Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N.Engl. J. Med. 2013, 368:107-116.
72. Jorissen E., Prox J., Bernreuther C., Weber S., Schwanbeck R., Serneels L., Snellinx A., Craessaerts K., Thathiah A., Tesseur I., et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J.Neurosci. 2010, 30:4833-4844.
73. *4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease. Neurosci. Lett. 1999, 263:129-132.
74. Karch C.M., Jeng A.T., Goate A.M. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J.Biol. Chem. 2012, 287:42751-42762.
75. Karch C.M., Jeng A.T., Goate A.M. Calcium phosphatase calcineurin influences tau metabolism. Neurobiol. Aging 2013, 34:374-386.
76. Kauwe J.S., Jacquart S., Chakraverty S., Wang J., Mayo K., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann. Neurol. 2007, 61:446-453.
77. Kauwe J.S.K., Cruchaga C., Mayo K., Fenoglio C., Bertelsen S., Nowotny P., Galimberti D., Scarpini E., Morris J.C., Fagan A.M., et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc. Natl. Acad. Sci. USA 2008, 105:8050-8054.
78. Kauwe J.S.K., Wang J., Mayo K., Morris J.C., Fagan A.M., Holtzman D.M., Goate A.M. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 2009, 10:13-17.
79. Kauwe J.S.K., Cruchaga C., Karch C.M., Sadler B., Lee M., Mayo K., Latu W., Su'a M., Fagan A.M., Holtzman D.M., et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS ONE 2011, 6:e15918. Alzheimer's Disease Neuroimaging Initiative.
80. Keenan B.T., Shulman J.M., Chibnik L.B., Raj T., Tran D., Sabuncu M.R., Allen A.N., Corneveaux J.J., Hardy J.A., Huentelman M.J., et al. A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. Hum. Mol. Genet. 2012, 21:2377-2388. Alzheimer's Disease Neuroimaging Initiative.
81. Kelley B.J., Haidar W., Boeve B.F., Baker M., Shiung M., Knopman D.S., Rademakers R., Hutton M., Adamson J., Kuntz K.M., et al. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch. Neurol. 2010, 67:171-177.
82. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
83. Kim M., Suh J., Romano D., Truong M.H., Mullin K., Hooli B., Norton D., Tesco G., Elliott K., Wagner S.L., et al. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate alpha-secretase activity. Hum. Mol. Genet. 2009, 18:3987-3996.
84. Kim J., Jiang H., Park S., Eltorai A.E., Stewart F.R., Yoon H., Basak J.M., Finn M.B., Holtzman D.M. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J.Neurosci. 2011, 31:18007-18012.
85. Kim S., Swaminathan S., Shen L., Risacher S.L., Nho K., Foroud T., Shaw L.M., Trojanowski J.Q., Potkin S.G., Huentelman M.J., et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79. Alzheimer's Disease Neuroimaging Initiative.
86. Kim W.S., Li H., Ruberu K., Chan S., Elliott D.A., Low J.K., Cheng D., Karl T., Garner B. Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease. J.Neurosci. 2013, 33:4387-4394.
87. Koten J.W., Wood G., Hagoort P., Goebel R., Propping P., Willmes K., Boomsma D.I. Genetic contribution to variation in cognitive function: an FMRI study in twins. Science 2009, 323:1737-1740.
88. Kovacs D.M., Fausett H.J., Page K.J., Kim T.W., Moir R.D., Merriam D.E., Hollister R.D., Hallmark O.G., Mancini R., Felsenstein K.M., et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat. Med. 1996, 2:224-229.
89. Kuhn P.H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Rossner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29:3020-3032.
90. Lai K.O., Ip N.Y. Synapse development and plasticity: roles of ephrin/Eph receptor signaling. Curr. Opin. Neurobiol. 2009, 19:275-283.
91. Lambert J.-C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099. European Alzheimer's Disease Initiative Investigators.
92. Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013, 45:1452-1458. European Alzheimer's Disease Initiative (EADI), Genetic and Environmental Risk in Alzheimer's DiseaseGenetic and Environmental Risk in Alzheimer's Disease, Alzheimer's Disease Genetic ConsortiumAlzheimer's Disease Genetic Consortium, Cohorts for Heart and Aging Research in Genomic EpidemiologyCohorts for Heart and Aging Research in Genomic Epidemiology.
93. Larner A.J., Ray P.S., Doran M. The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer's disease. J.Neurol. Sci. 2007, 252:173-176.
94. Lattante S., Le Ber I., Camuzat A., Dayan S., Godard C., Van Bortel I., De Septenville A., Ciura S., Brice A., Kabashi E. TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia. Neurobiol. Aging 2013, 34:e1-e2. French Research Network on FTD and FTD-ALS.
95. Laws S.M., Friedrich P., Diehl-Schmid J., Müller J., Eisele T., Bäuml J., Förstl H., Kurz A., Riemenschneider M. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol. Psychiatry 2007, 12:510-517.
96. Lindquist S.G., Holm I.E., Schwartz M., Law I., Stokholm J., Batbayli M., Waldemar G., Nielsen J.E. Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. Eur. J. Neurol. 2008, 15:377-385.
97. Lindquist S.G., Schwartz M., Batbayli M., Waldemar G., Nielsen J.E. Genetic testing in familial AD and FTD: mutation and phenotype spectrum in a Danish cohort. Clin. Genet. 2009, 76:205-209.
98. Liu D., Niu Z.X. The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacol. Immunotoxicol. 2009, 31:524-535.
99. Liu G., Yao L., Liu J., Jiang Y., Ma G., Chen Z., Zhao B., Li K. Cardiovascular disease contributes to Alzheimer's disease: evidence from large-scale genome-wide association studies. Neurobiol. Aging 2014, 35:786-792. Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium.
100. Lu P.H., Thompson P.M., Leow A., Lee G.J., Lee A., Yanovsky I., Parikshak N., Khoo T., Wu S., Geschwind D., Bartzokis G. Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. J.Alzheimers Dis. 2011, 23:433-442.
101. Ludolph A.C., Kassubek J., Landwehrmeyer B.G., Mandelkow E., Mandelkow E.M., Burn D.J., Caparros-Lefebvre D., Frey K.A., de Yebenes J.G., Gasser T., et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 2009, 16:297-309. Reisensburg Working Group for Tauopathies With Parkinsonism.
102. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
103. Mahley R.W., Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 2012, 76:871-885.
104. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000, 1:507-537.
105. Mattsson N., Andreasson U., Persson S., Carrillo M.C., Collins S., Chalbot S., Cutler N., Dufour-Rainfray D., Fagan A.M., Heegaard N.H., et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013, 9:251-261. Alzheimer's Association QC Program Work Group.
106. McMahon H.T., Wigge P., Smith C. Clathrin interacts specifically with amphiphysin and is displaced by dynamin. FEBS Lett. 1997, 413:319-322.
107. Mecozzi V.J., Berman D.E., Simoes S., Vetanovetz C., Awal M.R., Patel V.M., Schneider R.T., Petsko G.A., Ringe D., Small S.A. Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 2014, 10:443-449.
108. Medway C.W., Abdul-Hay S., Mims T., Ma L., Bisceglio G., Zou F., Pankratz S., Sando S.B., Aasly J.O., Barcikowska M., et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol. Neurodegener. 2014, 9:11.
109. Miyashita A., Koike A., Jun G., Wang L.S., Takahashi S., Matsubara E., Kawarabayashi T., Shoji M., Tomita N., Arai H., et al. SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS ONE 2013, 8:e58618. Alzheimer Disease Genetics Consortium.
110. Momeni P., Pittman A., Lashley T., Vandrovcova J., Malzer E., Luk C., Hulette C., Lees A., Revesz T., Hardy J., de Silva R. Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation. Neurobiol. Aging 2009, 30:388-393.
111. Moskvina V., Harold D., Russo G., Vedernikov A., Sharma M., Saad M., Holmans P., Bras J.M., Bettella F., Keller M.F., et al. Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. JAMA Neurol. 2013, 70:1268-1276. IPDGC and GERAD Investigators.
112. Moulder K.L., Snider B.J., Mills S.L., Buckles V.D., Santacruz A.M., Bateman R.J., Morris J.C. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res. Ther. 2013, 5:48.
113. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1992, 1:345-347.
114. Naj A.C., Jun G., Beecham G.W., Wang L.-S., Vardarajan B.N., Buros J., Gallins P.J., Buxbaum J.D., Jarvik G.P., Crane P.K., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43:436-441.
115. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 2001, 4:887-893.
116. Ostojic J., Elfgren C., Passant U., Nilsson K., Gustafson L., Lannfelt L., Froelich Fabre S. The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dement. Geriatr. Cogn. Disord. 2004, 17:298-301.
117. Paloneva J., Mandelin J., Kiialainen A., Bohling T., Prudlo J., Hakola P., Haltia M., Konttinen Y.T., Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J.Exp. Med. 2003, 198:669-675.
118. Peterson D., Munger C., Crowley J., Corcoran C., Cruchaga C., Goate A.M., Norton M.C., Green R.C., Munger R.G., Breitner J.C., et al. Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study. Alzheimers Dement. 2014, 10:366-371. Alzheimer's Disease Neuroimaging Initiative.
119. Pooler A.M., Phillips E.C., Lau D.H., Noble W., Hanger D.P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013, 14:389-394.
120. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., Prinzen C., Endres K., Hiemke C., Blessing M., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J.Clin. Invest. 2004, 113:1456-1464.
121. Potkin S.G., Guffanti G., Lakatos A., Turner J.A., Kruggel F., Fallon J.H., Saykin A.J., Orro A., Lupoli S., Salvi E., et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS ONE 2009, 4:e6501. Alzheimer's Disease Neuroimaging Initiative.
122. Potter R., Patterson B.W., Elbert D.L., Ovod V., Kasten T., Sigurdson W., Mawuenyega K., Blazey T., Goate A., Chott R., et al. Increased invivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med. 2013, 5:89ra77.
123. Rademakers R., Dermaut B., Peeters K., Cruts M., Heutink P., Goate A., Van Broeckhoven C. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Hum. Mutat. 2003, 22:409-411.
124. Rademakers R., Baker M., Gass J., Adamson J., Huey E.D., Momeni P., Spina S., Coppola G., Karydas A.M., Stewart H., et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007, 6:857-868.
125. Rajagopalan P., Hibar D.P., Thompson P.M. TREM2 and neurodegenerative disease. N.Engl. J. Med. 2013, 369:1565-1567.
126. Ramanan V.K., Risacher S.L., Nho K., Kim S., Swaminathan S., Shen L., Foroud T.M., Hakonarson H., Huentelman M.J., Aisen P.S., et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol. Psychiatry 2014, 19:351-357. Alzheimer's Disease Neuroimaging Initiative.
127. Rayaprolu S., Mullen B., Baker M., Lynch T., Finger E., Seeley W.W., Hatanpaa K.J., Lomen-Hoerth C., Kertesz A., Bigio E.H., et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variantwith frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 2013, 8:19.
128. Reed L.A., Grabowski T.J., Schmidt M.L., Morris J.C., Goate A., Solodkin A., Van Hoesen G.W., Schelper R.L., Talbot C.J., Wragg M.A., Trojanowski J.Q. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann. Neurol. 1997, 42:564-572.
129. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. USA 2005, 102:8299-8302.
130. Reitz C., Tosto G., Vardarajan B., Rogaeva E., Ghani M., Rogers R.S., Conrad C., Haines J.L., Pericak-Vance M.A., Fallin M.D., et al. Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP). Transcult. Psychiatry 2013, 3:e256. Alzheimer's Disease Genetics Consortium (ADGC).
131. Ridge P.G., Mukherjee S., Crane P.K., Kauwe J.S. Alzheimer's disease: analyzing the missing heritability. PLoS ONE 2013, 8:e79771. Alzheimer's Disease Genetics Consortium.
132. Rogaeva E.A., Fafel K.C., Song Y.Q., Medeiros H., Sato C., Liang Y., Richard E., Rogaev E.I., Frommelt P., Sadovnick A.D., et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 2001, 57:621-625.
133. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39:168-177.
134. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A.D., et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J.Clin. Invest. 1994, 94:860-869.
135. Sandbrink R., Zhang D., Schaeffer S., Masters C.L., Bauer J., Förstl H., Beyreuther K. Missense mutations of the PS-1/S182 gene in German early-onset Alzheimer's disease patients. Ann. Neurol. 1996, 40:265-266.
136. Scacchi R., Gambina G., Moretto G., Corbo R.M. A mutation screening by DHPLC of PSEN1 and APP genes reveals no significant variation associated with the sporadic late-onset form of Alzheimer's disease. Neurosci. Lett. 2007, 418:282-285.
137. Schmidt V., Sporbert A., Rohe M., Reimer T., Rehm A., Andersen O.M., Willnow T.E. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J.Biol. Chem. 2007, 282:32956-32964.
138. Schraml F., Chen K., Ayutyanont N., Auttawut R., Langbaum J.B., Lee W., Liu X., Bandy D., Reeder S.Q., Alexander G.E., et al. Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene Dose. PLoS ONE 2013, 8:e67163. the Alzheimer's Disease Neuroimaging Initiative.
139. Schürmann B., Wiese B., Bickel H., Weyerer S., Riedel-Heller S.G., Pentzek M., Bachmann C., Williams J., van den Bussche H., Maier W., Jessen F. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J.Alzheimers Dis. 2011, 25:421-424.
140. Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840. CHARGE Consortium, GERAD1 ConsortiumGERAD1 Consortium, EADI1 ConsortiumEADI1 Consortium.
141. Shen Y., Lue L., Yang L., Roher A., Kuo Y., Strohmeyer R., Goux W.J., Lee V., Johnson G.V., Webster S.D., et al. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 2001, 305:165-168.
142. Shen L., Thompson P.M., Potkin S.G., Bertram L., Farrer L.A., Foroud T.M., Green R.C., Hu X., Huentelman M.J., Kim S., et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav. 2014, 8:183-207. Alzheimer's Disease Neuroimaging Initiative.
143. Sherva R., Tripodis Y., Bennett D.A., Chibnik L.B., Crane P.K., de Jager P.L., Farrer L.A., Saykin A.J., Shulman J.M., Naj A., et al. Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimers Dement. 2014, 10:45-52. GENAROAD Consortium, Alzheimer's Disease Neuroimaging InitiativeAlzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Genetics ConsortiumAlzheimer's Disease Genetics Consortium.
144. Shulman J.M., Imboywa S., Giagtzoglou N., Powers M.P., Hu Y., Devenport D., Chipendo P., Chibnik L.B., Diamond A., Perrimon N., et al. Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms. Hum. Mol. Genet. 2014, 23:870-877.
145. Siest G., Pillot T., Régis-Bailly A., Leininger-Muller B., Steinmetz J., Galteau M.M., Visvikis S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin. Chem. 1995, 41:1068-1086.
146. Singleton A.B., Hardy J., Traynor B.J., Houlden H. Towards a complete resolution of the genetic architecture of disease. Trends Genet. 2010, 26:438-442.
147. Smith K.R., Damiano J., Franceschetti S., Carpenter S., Canafoglia L., Morbin M., Rossi G., Pareyson D., Mole S.E., Staropoli J.F., et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 2012, 90:1102-1107.
148. Spoelgen R., von Arnim C.A., Thomas A.V., Peltan I.D., Koker M., Deng A., Irizarry M.C., Andersen O.M., Willnow T.E., Hyman B.T. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J.Neurosci. 2006, 26:418-428.
149. Stein J.L., Medland S.E., Vasquez A.A., Hibar D.P., Senstad R.E., Winkler A.M., Toro R., Appel K., Bartecek R., Bergmann O., et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat. Genet. 2012, 44:552-561. Alzheimer's Disease Neuroimaging Initiative, EPIGEN ConsortiumEPIGEN Consortium, IMAGEN ConsortiumIMAGEN Consortium, Saguenay Youth Study GroupSaguenay Youth Study Group, Cohorts for Heart and Aging Research in Genomic Epidemiology ConsortiumCohorts for Heart and Aging Research in Genomic Epidemiology Consortium, Enhancing Neuro Imaging Genetics through Meta-Analysis ConsortiumEnhancing Neuro Imaging Genetics through Meta-Analysis Consortium.
150. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:8098-8102.
151. Suh J., Choi S.H., Romano D.M., Gannon M.A., Lesinski A.N., Kim D.Y., Tanzi R.E. ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Neuron 2013, 80:385-401.
152. Swan M., Saunders-Pullman R. The association between ß-glucocerebrosidase mutations and parkinsonism. Curr. Neurol. Neurosci. Rep. 2013, 13:368.
153. Taddei K., Fisher C., Laws S.M., Martins G., Paton A., Clarnette R.M., Chung C., Brooks W.S., Hallmayer J., Miklossy J., et al. Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Mol. Psychiatry 2002, 7:776-781.
154. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.-O., Westman E., Kinsey A., Güntert A., et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 2010, 67:739-748.
155. Thinakaran G., Koo E.H. Amyloid precursor protein trafficking, processing, and function. J.Biol. Chem. 2008, 283:29615-29619.
156. Thompson P.M., Cannon T.D., Narr K.L., van Erp T., Poutanen V.P., Huttunen M., Lönnqvist J., Standertskjöld-Nordenstam C.G., Kaprio J., Khaledy M., et al. Genetic influences on brain structure. Nat. Neurosci. 2001, 4:1253-1258.
157. Thompson P.M., Stein J.L., Medland S.E., Hibar D.P., Vasquez A.A., Renteria M.E., Toro R., Jahanshad N., Schumann G., Franke B., et al. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav. 2014, 8:153-182. Alzheimer's Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group.
158. Tolboom N., Koedam E.L., Schott J.M., Yaqub M., Blankenstein M.A., Barkhof F., Pijnenburg Y.A., Lammertsma A.A., Scheltens P., van Berckel B.N. Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings. Alzheimer Dis. Assoc. Disord. 2010, 24:303-307.
159. Tomaino C., Bernardi L., Anfossi M., Costanzo A., Ferrise F., Gallo M., Geracitano S., Maletta R., Curcio S.A., Mirabelli M., et al. Presenilin 2 Ser130Leu mutation in a case of late-onset "sporadic" Alzheimer's disease. J.Neurol. 2007, 254:391-393.
160. Van Deerlin V.M., Wood E.M., Moore P., Yuan W., Forman M.S., Clark C.M., Neumann M., Kwong L.K., Trojanowski J.Q., Lee V.M., Grossman M. Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch. Neurol. 2007, 64:1148-1153.
161. Vellas B., Carrillo M.C., Sampaio C., Brashear H.R., Siemers E., Hampel H., Schneider L.S., Weiner M., Doody R., Khachaturian Z., et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013, 9:438-444. EU/US/CTAD Task Force Members.
162. Verghese P.B., Castellano J.M., Garai K., Wang Y., Jiang H., Shah A., Bu G., Frieden C., Holtzman D.M. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc. Natl. Acad. Sci. USA 2013, 110:E1807-E1816.
163. Wakabayashi T., De Strooper B. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 2008, 23:194-204.
164. Wijsman E.M., Pankratz N.D., Choi Y., Rothstein J.H., Faber K.M., Cheng R., Lee J.H., Bird T.D., Bennett D.A., Diaz-Arrastia R., et al. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011, 7:e1001308. NIA-LOAD/NCRAD Family Study Group.
165. Wojtas A., Heggeli K.A., Finch N., Baker M., Dejesus-Hernandez M., Younkin S.G., Dickson D.W., Graff-Radford N.R., Rademakers R. C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. Am J Neurodegener Dis 2012, 1:107-118.
166. Wolf A.B., Valla J., Bu G., Kim J., LaDu M.J., Reiman E.M., Caselli R.J. Apolipoprotein E as a β-amyloid-independent factor in Alzheimer's disease. Alzheimers Res. Ther. 2013, 5:38.
167. Wray N.R., Goddard M.E., Visscher P.M. Prediction of individual genetic risk of complex disease. Curr. Opin. Genet. Dev. 2008, 18:257-263.
168. Wunderlich P., Glebov K., Kemmerling N., Tien N.T., Neumann H., Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and γ-secretase-dependent intramembranous cleavage. J.Biol. Chem. 2013, 288:33027-33036.
169. Xiao Q., Gil S.C., Yan P., Wang Y., Han S., Gonzales E., Perez R., Cirrito J.R., Lee J.M. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J.Biol. Chem. 2012, 287:21279-21289.
170. Xing Y.Y., Yu J.T., Cui W.Z., Zhong X.L., Wu Z.C., Zhang Q., Tan L. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J.Alzheimers Dis. 2012, 29:515-519.
171. Yamada K., Holth J.K., Liao F., Stewart F.R., Mahan T.E., Jiang H., Cirrito J.R., Patel T.K., Hochgräfe K., Mandelkow E.M., Holtzman D.M. Neuronal activity regulates extracellular tau invivo. J.Exp. Med. 2014, 211:387-393.
172. Yates P.A., Desmond P.M., Phal P.M., Steward C., Szoeke C., Salvado O., Ellis K.A., Martins R.N., Masters C.L., Ames D., et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology 2014, 82:1266-1273. AIBL Research Group.
173. Yoshikai S., Sasaki H., Doh-ura K., Furuya H., Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 1990, 87:257-263.
174. Zhang B., Gaiteri C., Bodea L.G., Wang Z., McElwee J., Podtelezhnikov A.A., Zhang C., Xie T., Tran L., Dobrin R., et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013, 153:707-720.